HKSE - Delayed Quote HKD
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566.HK)
6.090
+0.070
+(1.16%)
At close: 4:08:33 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,369,184
1,369,184
1,287,408
1,125,405
1,307,251
Cost of Revenue
287,505
287,505
296,739
271,143
356,844
Gross Profit
1,081,679
1,081,679
990,669
854,262
950,407
Operating Expense
900,914
900,914
844,971
793,222
814,359
Operating Income
180,765
180,765
145,698
61,040
136,048
Net Non Operating Interest Income Expense
-5,863
-5,863
-9,103
-8,858
-9,401
Pretax Income
168,628
168,628
134,932
51,419
127,535
Tax Provision
30,027
30,027
15,157
-8,448
8,122
Net Income Common Stockholders
138,601
138,601
119,775
59,867
119,413
Diluted NI Available to Com Stockholders
138,601
138,601
119,775
59,867
119,413
Basic EPS
0.68
--
0.49
0.24
0.49
Diluted EPS
0.68
--
0.49
0.24
0.49
Basic Average Shares
204,228.929
--
245,398.800
245,398.800
245,398.800
Diluted Average Shares
204,228.929
--
245,398.800
245,398.800
245,398.800
Total Expenses
1,188,419
1,188,419
1,141,710
1,064,365
1,171,203
Net Income from Continuing & Discontinued Operation
138,601
138,601
119,775
59,867
119,413
Normalized Income
138,601
138,601
119,775
60,214.250
119,338.095
Interest Income
1,282
1,282
283
184
319
Interest Expense
7,145
7,145
9,386
9,042
9,720
Net Interest Income
-5,863
-5,863
-9,103
-8,858
-9,401
EBIT
175,773
175,773
144,318
60,461
137,255
EBITDA
212,712
212,712
180,453
96,231
161,499
Reconciled Cost of Revenue
287,505
287,505
296,739
271,143
356,844
Reconciled Depreciation
36,939
36,939
36,135
35,770
24,244
Net Income from Continuing Operation Net Minority Interest
138,601
138,601
119,775
59,867
119,413
Total Unusual Items Excluding Goodwill
--
--
-1,219
-463
80
Total Unusual Items
--
--
-1,219
-463
80
Normalized EBITDA
212,712
212,712
180,453
96,694
161,419
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
-115.750
5.095
12/31/2021 - 11/28/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade